CN112638935A - 一种类风湿性关节炎自体抗体结合的肽及其应用 - Google Patents

一种类风湿性关节炎自体抗体结合的肽及其应用 Download PDF

Info

Publication number
CN112638935A
CN112638935A CN202080004129.3A CN202080004129A CN112638935A CN 112638935 A CN112638935 A CN 112638935A CN 202080004129 A CN202080004129 A CN 202080004129A CN 112638935 A CN112638935 A CN 112638935A
Authority
CN
China
Prior art keywords
rheumatoid arthritis
peptide
antibody
blood sample
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080004129.3A
Other languages
English (en)
Inventor
蔡嘉哲
彭心仪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Medical University
Original Assignee
China Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Medical University filed Critical China Medical University
Publication of CN112638935A publication Critical patent/CN112638935A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C07K17/12—Cellulose or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种能与类风湿性关节炎自体抗体结合的肽,其具有与类风湿性关节炎的自体抗体结合的抗原决定位点。进一步提供了利用所述肽检测类风湿性关节炎疾病的方法。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080004129.3A 2019-01-27 2020-01-20 一种类风湿性关节炎自体抗体结合的肽及其应用 Pending CN112638935A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797351P 2019-01-27 2019-01-27
US62/797,351 2019-01-27
PCT/CN2020/073097 WO2020151631A1 (zh) 2019-01-27 2020-01-20 一种类风湿性关节炎自体抗体结合的肽及其应用

Publications (1)

Publication Number Publication Date
CN112638935A true CN112638935A (zh) 2021-04-09

Family

ID=71735682

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080004129.3A Pending CN112638935A (zh) 2019-01-27 2020-01-20 一种类风湿性关节炎自体抗体结合的肽及其应用

Country Status (4)

Country Link
US (1) US12105097B2 (zh)
CN (1) CN112638935A (zh)
TW (1) TWI744777B (zh)
WO (1) WO2020151631A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602426A (zh) * 2001-12-11 2005-03-30 技术科学基金会 从患有类风湿性关节炎的患者中检测自身抗体的方法、肽和检测试剂盒
CN102971339A (zh) * 2010-07-02 2013-03-13 托斯卡纳生物标志有限公司 组蛋白瓜氨酸肽及其应用
CN104262489A (zh) * 2014-09-30 2015-01-07 陈仁奋 一种环状瓜氨酸嵌合肽抗原及其应用
CN104987366A (zh) * 2014-08-21 2015-10-21 上海市东方医院 一种类风湿关节炎自身抗体结合抗原及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US9732143B2 (en) * 2011-02-03 2017-08-15 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602426A (zh) * 2001-12-11 2005-03-30 技术科学基金会 从患有类风湿性关节炎的患者中检测自身抗体的方法、肽和检测试剂盒
CN102971339A (zh) * 2010-07-02 2013-03-13 托斯卡纳生物标志有限公司 组蛋白瓜氨酸肽及其应用
CN104987366A (zh) * 2014-08-21 2015-10-21 上海市东方医院 一种类风湿关节炎自身抗体结合抗原及其应用
CN104262489A (zh) * 2014-09-30 2015-01-07 陈仁奋 一种环状瓜氨酸嵌合肽抗原及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LINDA JOHANSSON等: "Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis，PubMed，Porphyromonas gingivalis and arg-gingipain and rheumatoid arthritis", 《ARTHRITIS RESEARCH & THERAPY》 *
TIM STOBERNACK等: "Extracellular Proteome and Citrullinome of the Oral Pathogen Porphyromonas gingivalis", 《JOURNAL OF PROTEOME RESEARCH》 *
YURIKO YASAKI-INAGAKI等: "Production of protective antibodies against Porphyromonas gingivalis strains by immunization with recombinant gingipain domains", 《FEMS IMMUNOL MED MICROBIOL》 *

Also Published As

Publication number Publication date
TW202041523A (zh) 2020-11-16
WO2020151631A1 (zh) 2020-07-30
US20210341491A1 (en) 2021-11-04
TWI744777B (zh) 2021-11-01
US12105097B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
Božič et al. Sera from patients with rheumatic diseases recognize different epitope regions on the 52‐kD Ro/SS‐A protein
JPH09512630A (ja) 診断マーカーとしてのヒト好中球リポカリン（ｈｎｌ）の使用および抗−ｈｎｌ−抗体調製物
Kurasawa et al. Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus
Falkenburg et al. Anti-hinge antibodies recognize IgG subclass–and protease-restricted neoepitopes
KR20160123238A (ko) 스틸씨병 진단용 바이오마커 조성물, 진단 키트 및 진단 방법
WO2018119626A1 (zh) 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒
Rajaei et al. Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity
Won et al. Pathogenic role of circulating citrullinated antigens and anti-cyclic monoclonal citrullinated peptide antibodies in rheumatoid arthritis
St Clair et al. Temporal correlation of antibody responses to different epitopes of the human La autoantigen.
Perosa et al. Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis
JP6687391B2 (ja) リウマチ性関節炎（ｒａ）の存在を決定するためのサンプルの測定方法
CN112638935A (zh) 一种类风湿性关节炎自体抗体结合的肽及其应用
JP6122779B2 (ja) 抗ｗｔ１抗体の測定方法
EP2653871B1 (en) Novel test method for rheumatoid arthritis and kit for rheumatoid arthritis test
Hussain et al. Moesin expression is correlated with its involvement in patients with Behcet’s disease
Costa et al. Detection of antibodies to histones in human systemic lupus erythematosus and in murine lupus-like syndromes using micro-ELISA
JPH08508093A (ja) 膵臓線維症又はｃｆｔｒ遺伝子の突然変異の検出
Nakachi et al. Epitopes recognised by tissue transglutaminase antibodies in coeliac disease
JPWO2006004207A1 (ja) 抗シノビオリン抗体
Choi et al. Clinical significance of anti-filaggrin antibody recognizing uncitrullinated filaggrin in rheumatoid arthritis
US20140322211A1 (en) Tenascin-c and use thereof in rheumatoid arthritis
KR102121927B1 (ko) Tcp1 자가항체를 이용한 전신홍반성루푸스 진단방법
RU2550255C2 (ru) РЕКОМБИНАНТНАЯ ДНК pA3, РЕКОМБИНАНТНАЯ ДНК pQE 30-pA3, ОБЕСПЕЧИВАЮЩИЕ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A3, ШТАММ E. coli М 15-A3, ТРАНСФОРМИРОВАННЫЙ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pQE 30-pA3 И ЭКСПРЕССИРУЮЩИЙ РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД A3, РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД A3, ОБЛАДАЮЩИЙ СПОСОБНОСТЬЮ СЕЛЕКТИВНО СВЯЗЫВАТЬ ЧСА, И ТЕСТ-СИСТЕМА РФА ДЛЯ КАЧЕСТВЕННОГО ВЫЯВЛЕНИЯ МИКРОАЛЬБУМИНУРИИ, ТЕСТ-СИСТЕМА ДЛЯ КОЛИЧЕСТВЕННОГО ОПРЕДЕЛЕНИЯ МИКРОАЛЬБУМИНУРИИ
KR102109105B1 (ko) Smyd3 자가항체를 이용한 전신홍반성루푸스 진단방법
CN103509087A (zh) 抗CiP抗体在早期类风湿关节炎诊断中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination